Relates to patient counseling before issuing a prescription for a schedule II opioid; requires practitioners to consult with the patient regarding the quantity of the opioid and the patient's option to fill the prescription in a lesser quantity, and to inform the patient of the risks associated with opiate addiction and document the reason for the prescription.
Summary
Bill S05260 aims to amend the public health law in New York by instituting mandatory patient counseling before the issuance of prescriptions for schedule II opioids. Specifically, it requires practitioners to consult with patients about the quantity of the opioid prescribed, inform them of the risks associated with opiate addiction, and document the rationale for the prescription in the patient's medical record. This initiative seeks to enhance patient awareness and safety regarding opioid use.
Impact
If enacted, this bill would significantly impact the prescribing practices for schedule II opioids in New York. It would require healthcare providers to engage in more thorough discussions with patients, potentially leading to a reduction in opioid misuse and addiction. The documentation requirement may also affect medical record-keeping practices and could lead to increased accountability among practitioners.
Sentiment
The sentiment surrounding Bill S05260 appears to be generally supportive, as it addresses critical issues related to opioid addiction and patient safety. However, there may be concerns regarding the additional burden placed on healthcare providers in terms of time and resources needed to comply with the new counseling requirements.
Contention
Notable points of contention may arise from healthcare providers who feel that the additional counseling requirements could hinder their ability to prescribe necessary medications efficiently. Some may argue that the bill could lead to delays in patient care, while advocates for the bill emphasize the importance of informed consent and patient education in combating the opioid crisis.
Same As
Relates to patient counseling before issuing a prescription for a schedule II opioid; requires practitioners to consult with the patient regarding the quantity of the opioid and the patient's option to fill the prescription in a lesser quantity, and to inform the patient of the risks associated with opiate addiction and document the reason for the prescription.
Relates to patient counseling before issuing a prescription for a schedule II opioid; requires practitioners to consult with the patient regarding the quantity of the opioid and the patient's option to fill the prescription in a lesser quantity, and to inform the patient of the risks associated with opiate addiction and document the reason for the prescription.
Relates to patient counseling before issuing a prescription for a schedule II opioid; requires practitioners to consult with the patient regarding the quantity of the opioid and the patient's option to fill the prescription in a lesser quantity, and to inform the patient of the risks associated with opiate addiction and document the reason for the prescription.
Requires practitioners to provide counselling to patients about the potential addictive properties of opioids prior to prescribing such medications; requires pharmacists to provide counselling to patients about the potential addictive properties of opioids at the time a prescription for opioids is filled.
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.